Polar Asset Management Partners Inc. Raises Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Polar Asset Management Partners Inc. lifted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 1,318.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 137,550 shares of the biopharmaceutical company's stock after acquiring an additional 127,850 shares during the quarter. Polar Asset Management Partners Inc. owned 0.21% of Celldex Therapeutics worth $3,476,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its holdings in shares of Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 878 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics during the 4th quarter worth approximately $81,000. KBC Group NV lifted its holdings in Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 1,647 shares in the last quarter. AlphaQuest LLC lifted its holdings in Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after buying an additional 2,705 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in Celldex Therapeutics during the 4th quarter worth approximately $121,000.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Tuesday, May 6th. The Goldman Sachs Group dropped their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Morgan Stanley dropped their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. UBS Group dropped their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, Canaccord Genuity Group started coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They issued a "buy" rating and a $64.00 target price on the stock. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Celldex Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $53.90.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock traded down $0.49 during midday trading on Wednesday, hitting $20.01. 668,334 shares of the company's stock were exchanged, compared to its average volume of 892,877. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $47.00. The firm's 50 day simple moving average is $18.91 and its 200 day simple moving average is $22.51. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -7.82 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The business had revenue of $0.70 million for the quarter, compared to analysts' expectations of $1.08 million. On average, equities research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.